Stylianos A Kandarakis, Nikolaos Spernovasilis, Ilias Georgalas, Michalis Mendris, Constantinos Tsioutis, Aris P Agouridis
{"title":"Endophthalmitis caused by <i>Enterococcus casseliflavus:</i> a systematic review of literature.","authors":"Stylianos A Kandarakis, Nikolaos Spernovasilis, Ilias Georgalas, Michalis Mendris, Constantinos Tsioutis, Aris P Agouridis","doi":"10.18683/germs.2023.1404","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong><i>Enterococcus casseliflavus</i> is a rare pathogen in human infections, despite being widely distributed in natural environments. This systematic review aims to evaluate the evidence related to endophthalmitis caused by <i>E. casseliflavus</i>.</p><p><strong>Methods: </strong>A thorough search of PubMed, PubMed Central, and Scopus databases was conducted, covering the period up to October 2022.</p><p><strong>Results: </strong>A total of 53 records were identified, with 8 studies reporting a total of 21 cases meeting the inclusion criteria. Among these studies, 7 described isolated case reports, while 1 study described 14 cases. The overall quality of the reports was good, as all articles were determined to have low risk of bias. Vancomycin susceptibility was reported in only one case of isolated case reports, while the remaining cases were all vancomycin resistant. With regard to management, in most cases intravenous ampicillin and linezolid were administered, while only one study reported administration of vancomycin.</p><p><strong>Conclusions: </strong>Ophthalmologists should be aware of the potential for <i>E. casseliflavus</i> to cause endophthalmitis infections and the challenges associated with its intrinsic resistance to vancomycin.</p>","PeriodicalId":45107,"journal":{"name":"GERMS","volume":"13 4","pages":"343-351"},"PeriodicalIF":1.7000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10866162/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GERMS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18683/germs.2023.1404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Enterococcus casseliflavus is a rare pathogen in human infections, despite being widely distributed in natural environments. This systematic review aims to evaluate the evidence related to endophthalmitis caused by E. casseliflavus.
Methods: A thorough search of PubMed, PubMed Central, and Scopus databases was conducted, covering the period up to October 2022.
Results: A total of 53 records were identified, with 8 studies reporting a total of 21 cases meeting the inclusion criteria. Among these studies, 7 described isolated case reports, while 1 study described 14 cases. The overall quality of the reports was good, as all articles were determined to have low risk of bias. Vancomycin susceptibility was reported in only one case of isolated case reports, while the remaining cases were all vancomycin resistant. With regard to management, in most cases intravenous ampicillin and linezolid were administered, while only one study reported administration of vancomycin.
Conclusions: Ophthalmologists should be aware of the potential for E. casseliflavus to cause endophthalmitis infections and the challenges associated with its intrinsic resistance to vancomycin.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
